Anti-N-sulfated heparan sulfate PE

Anti-N-sulfated heparan sulfate PE
Regulatory status
RUO
Antigen
N-sulfated heparan sulfate
Clone
HepSS-1
Format
PE
Reactivity
Species independent
Application
FC (QC tested)
Excitation laser
blue (488 nm)
Variant
0.1 mg
1P-821-C100
In stock
Variant
0.1 mg
11-261-C100
In stock
Product details
References
Isotype
Mouse IgM
Specificity
The mouse monoclonal antibody HepSS-1 (also known as HepSS1) recognizes N-sulfated heparan sulfate (axtracellular antigen) present in many species.
Application
FC (QC tested)
Reactivity
Species independent
Immunogen
MethA murine fibrosarcoma
Other names
N-sulfo-rich heparan sulfate
Concentration
0.1 mg/ml
Preparation
The purified antibody is conjugated with R-phycoerythrin (PE) under optimum conditions. The conjugate is purified by size-exclusion chromatography.
Formulation
Stabilizing phosphate buffered saline (PBS) solution containing 15mM sodium azide
Storage and handling
Store in the dark at 2-8°C. Do not freeze. Avoid prolonged exposure to light. Do not use after expiration date stamped on vial label.
Exbio licence note
Unless indicated otherwise, all products are For Research Use Only and not for diagnostic use. In vivo diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s. © 2019 EXBIO Praha, a.s. All rights reserved.

Product specific references:

Kure S, Yoshie O: A syngeneic monoclonal antibody to murine Meth-A sarcoma (HepSS-1) recognizes heparan sulfate glycosaminoglycan (HS-GAG): cell density and transformation dependent alteration in cell surface HS-GAG defined by HepSS-1. J Immunol. 1986 Dec 15;137(12):3900-8.
PubMed
van den Born J, Salmivirta K, Henttinen T, Ostman N, Ishimaru T, Miyaura S, Yoshida K, Salmivirta M: Novel heparan sulfate structures revealed by monoclonal antibodies. J Biol Chem. 2005 May 27;280(21):20516-23.
PubMed
Lipscombe RJ, Nakhoul AM, Sanderson CJ, Coombe DR: Interleukin-5 binds to heparin/heparan sulfate. A model for an interaction with extracellular matrix. J Leukoc Biol. 1998 Mar;63(3):342-50.
PubMed
Crim RL, Audet SA, Feldman SA, Mostowski HS, Beeler JA: Identification of linear heparin-binding peptides derived from human respiratory syncytial virus fusion glycoprotein that inhibit infectivity. J Virol. 2007 Jan;81(1):261-71. Epub 2006 Oct 18.
PubMed
Chung JS, Shiue LH, Duvic M, Pandya A, Cruz PD Jr, Ariizumi K: Sézary syndrome cells overexpress syndecan-4 bearing distinct heparan sulfate moieties that suppress T-cell activation by binding DC-HIL and trapping TGF-beta on the cell surface. Blood. 2011 Mar 24;117(12):3382-90.
PubMed
Kure S, Yoshie O, Aso H: Metastatic potential of murine B16 melanoma correlates with reduced surface heparan sulfate glycosaminoglycan. Jpn J Cancer Res. 1987 Nov;78(11):1238-45.
PubMed
Mii Y, Yamamoto T, Takada R, Mizumoto S, Matsuyama M, Yamada S, Takada S, Taira M: Roles of two types of heparan sulfate clusters in Wnt distribution and signaling in Xenopus. Nat Commun. 2017 Dec 7;8(1):1973.
PubMed
Variant
0.1 mg
1P-821-C100
In stock
Variant
0.1 mg
11-261-C100
In stock